Email this article Bevatsizumab (Avastin) v kombinatsii s taksanami v 1-y linii lecheniya HER-2-negativnogo metastaticheskogo raka molochnoy zhelezy(Rezul'taty issledovaniya AVADO)
- Authors: Zhukova LG1
-
Affiliations:
- РОНЦ им. Н.Н.Блохина РАМН, Москва
- Issue: Vol 11, No 1 (2009)
- Pages: 22-24
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26755
- ID: 26755
Cite item
Full Text
Abstract
Значение таксанов (паклитаксела и доцетаксела) в терапии рака молочной железы (РМЖ) трудно переоценить. В апреле 1994 г. паклитаксел был одобрен к применению у больных с РМЖ, имеющих прогрессирование на стандартной антрациклинсодержащей химиотерапии или в течение 6 мес после окончания антрациклинсодержащей адъювантной терапии. А уже в мае 1996 г. ускоренную регистрацию FDA прошел и другой представитель таксанов – доцетаксел, показав значимое увеличение непосредственной эффективности и выживаемости у больных с РМЖ, имеющих прогрессирование после терапииантрациклинами или во время нее.В 2000 г. были опубликованы результаты 3 рандомизированных исследований (CALGB 9344, NSABP-B28 и исследование клиники M.D. Anderson), продемонстрировавших статистически достоверное увеличение выживаемости без прогрессирования и общей выживаемости (ОВ) у больных с ранним РМЖ, имеющих высокий риск прогрессирования, при проведении 4 дополнительных курсов паклитакселом после стандартных 4 курсов адъювантной химиотерапии АС или FAC.
Keywords
Full Text
##article.viewOnOriginalSite##References
- Nabholtz J.M., Senn H.J., Bezwoda W.R. et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline - containing chemotherapy. J Clin Oncol 1999; 17: 1413–24.
- Sjostrom J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194–201.
- Thomas E, Buzdar A, Theriault R et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of a prospective randomized clinical trial [abstract]. Proc ASCO 2000; 19: 74a.
- Mamounas E.P. Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary node. Proceedings from the NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer; 2000 Nov 1–3, 2000; Bethesda. Bethesda (MD): National Institutes of Health; 2000.
- Wolowacz S.E., Cameron D.A., Tate H.C., Bagust A.J. Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node - Positive Breast Cancer: A Cost - Effectiveness and Cost-Utility Analysis Clin Oncol 2008; 26: 925–33.
- Jones S.E., Savin M.A., Holmes F.A. et al. Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. J Clin Oncol Dec 2006; 24: 5381–7.
- O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline - pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812–23.
- Marty M, Cognetti F, Maraninchi D et al. Superior long - term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: Patients surviving more than 4 years in the M77001 study. Breast Cancer Res Treat 2006; 100 (suppl. 1): S103.
- Slamon D.J., Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92.
- Miller K, Wang M et al. Paclitaxel plus Bevacizumab versus Paclitaxel alone for Metastatic Breast cancer. N Engl J Med 2007; 357: 26.
- Klencke B.J. et al. Independent review of E 2100 progression free survival (PFS) with the addition of bevacizumab to paclitaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 2008; 26 (May 20) suppl.: abstr 1036.
- Wagner L, Wang M, Miller K et al. Health - related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S239 (abstr).
- Miles D, Chan A, Romieu G et al. Randomized, double - blind, placebo - controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first - line therapy for patients with locally recurrent or metastatic breast cancer: AVADO. ASCO 2008; abstr LBA 1011.
- Fumoleau P, Greil R, Rayson D et al. Bevacizumab maintenance therapy significantly delays disease progression or death compared with placebo in the AVADO trial. SABCS 2008. post. 903.
